HEPATOCELLULAR CARCINOMA (HCC)

This study tested whether adding a virus-based immunotherapy (Pexa-Vec) to the standard drug sorafenib helps people with advanced liver cancer live longer. About 459 adults with advanced liver cancer who had not received prior treatment took part. The approach uses a modified vir…

This completed study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard immunotherapy and anti-angiogenesis drugs improves outcomes for people with advanced liver cancer that has spread into the portal vein. Over 1,600 participants were included. The …

This study looked at adding a procedure called TACE (which blocks blood flow to tumors) to a mix of immunotherapy and anti-angiogenesis drugs for people with advanced liver cancer that has invaded major blood vessels. Over 2,600 participants were included to see if the triple com…

This study tested whether giving the immunotherapy drug pembrolizumab before and after a standard tumor-destroying procedure (ablation) could improve outcomes for 30 people with early-stage liver cancer. The goal was to see if the combination could shrink tumors and delay recurre…

This study looked at 300 adults with high-risk liver cancer who received a combination of two drugs (atezolizumab and bevacizumab) plus chemotherapy infused directly into the liver artery. The goal was to see how well this treatment worked and how safe it was in everyday medical …

This Phase 3 study tested a new immunotherapy drug, tislelizumab, against the standard targeted therapy sorafenib in 684 adults with advanced liver cancer that could not be removed by surgery. Participants received either tislelizumab intravenously every three weeks or sorafenib …

This completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …

This study tested a new ultrasound technique (Side-by-Side Contrast-Enhanced Ultrasound) to see if it could accurately check whether microwave ablation fully destroyed liver tumors just 1-3 days after treatment. Researchers compared it to standard contrast-enhanced ultrasound in …

This large completed trial tested whether an AI system can help radiologists better diagnose liver tumors from CT scans. Over 10,000 adults with various liver conditions participated. The AI analyzed scans overnight, and a senior radiologist reviewed any differences between the A…

This study analyzed data from 1005 liver cancer patients to see who benefits from a treatment called TACE after surgery. Using machine learning, researchers aimed to predict individual patient outcomes. The goal is to help doctors decide whether to recommend TACE or just monitor …

This study tested a computer model that helps surgeons decide the best type of surgery for patients with a rare form of liver cancer that has spread into the bile ducts. The model uses patient scans and medical history to recommend whether to remove part of the bile duct or just …

This study looked at 324 adults with intermediate-stage liver cancer to see if CT scan features could predict how well they would respond to a combination treatment of targeted therapy and a procedure that blocks the tumor's blood supply. The goal was to find out if certain scan …

This study looked back at data from 484 liver cancer patients who had a liver transplant to see if taking certain cancer drugs (tyrosine kinase inhibitors) before the transplant helped them live longer or kept the cancer from coming back. The researchers checked survival rates, c…

This completed study used artificial intelligence to analyze data from 7,000 liver cancer patients. The goal was to create a tool that helps doctors predict liver function, treatment outcomes, and cancer spread. The tool aims to guide personalized decisions about surgery, chemoth…